News

The series B financing round was headed by Sequoia China and LYFE Capital, and supported by existing series A investors such as VI Ventures and Nest.Bio Ventures and

Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments,

In the merger, each share of AveXis common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Merger Sub, AveXis

Retacrit has been indicated for the treatment of anemia resulting from chronic kidney disease, chemotherapy, or use of zidovudine in HIV-infected patients. The FDA has also approved Retacrit for treating anemia

Daiichi Sankyo oncology research and development global head and executive vice president Dr Antoine Yver said: “With a successful track record and our first bispecific antibody incorporating the

Indivior PLC and its U.S. subsidiary, Indivior Inc., marketers and distributors of SUBOXONE, joined partner Aquestive in the settlement with Par Pharmaceuticals, Inc., an operating company of Endo

AurKa Pharma was established as part of the TVM Life Science Ventures VII fund, to develop an Aurora kinase A inhibitor called AK-01. The oncology compound was discovered originally

The study has failed to achieve statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca is continuing the Terranova trial, which is also a

Under the development agreement, Hemogenyx will receive on a cost-free basis technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property which